Illumina Inc. (ILMN): Today's Featured Drugs Winner
(
) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.7%. By the end of trading, Illumina Inc rose 15 cents (0.6%) to $27.30 on light volume. Throughout the day, 561,583 shares of Illumina Inc exchanged hands as compared to its average daily volume of three million shares. The stock ranged in a price between $26.92-$27.69 after having opened the day at $26.94 as compared to the previous trading day's close of $27.15. Other companies within the Drugs industry that increased today were:
(
), up 44.8%,
(
), up 12.2%,
(
), up 11.6%, and
StemCells Inc
(
STEMD
), up 8.3%.
Illumina, Inc. develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Illumina Inc has a market cap of $3.3 billion and is part of the
sector. The company has a P/E ratio of 34.8, above the average drugs industry P/E ratio of 34.4 and above the S&P 500 P/E ratio of 17.7. Shares are down 57.1% year to date as of the close of trading on Wednesday.
TheStreet Ratings rates Illumina as a
. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and unimpressive growth in net income.
- You can view the full Illumina Ratings Report.
On the negative front,
(
), down 11.5%,
(
), down 9.1%,
(
), down 8.7%, and
(
), down 8.3%, were all losers within the drugs industry with
Teva Pharmaceutical Industries
(
) being today's drugs industry loser.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null
